Figure 2 Age-specific prevalence of common comorbidities

Slides:

Advertisements

Similar presentations

Essentials of CKD Comorbidities and outcomes in CKD.

Advertisements

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

The Attention-Deficit Hyperactivity Disorder Paradox: 2

J Browne, DA Edwards, KM Rhodes, DJ Brimicombe, RA Payne

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Figure 1 Perivenous distribution of multiple sclerosis lesions

Figure 2 The US Centers for Disease Control and

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Transition of Care in Epilepsy Among Patients Entering Long-Term Care

Figure 2 Copy-number variations in multiple myeloma

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 4 Neuromyelitis optica spectrum disorder brain lesions

Figure 4 Brainstem lesions and acute central vestibular syndrome

Figure 1 The burden of chronic kidney disease (CKD)

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Figure 2 Poststroke plasticity and recovery

Nat. Rev. Urol. doi: /nrurol

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Figure 2 Examples of lesions with and without central veins

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Lifestyle and environmental factors affect

Figure 1 Evolution of multiple sclerosis

Figure 2 Haemorrhagic stroke prevalence and mortality

Figure 1 The trajectory of cognitive ageing

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Anatomical patterns of neuropathy

Figure 1 Proportional motor recovery in the upper limb

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Diagnostic scheme for MSA

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 6 Combining population-wide and high-risk strategies

Figure 1 Ischaemic stroke prevalence and mortality

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Frequency of vertigo and dizziness syndromes

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Tau PET images in patients with Alzheimer disease

Figure 2 Cellular pathways implicated in CIPN

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 3 Temporal trends in FALS incidence

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 1 A large number of genes are potentially associated with CIPN

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Jean-Martin Charcot (1825–1893)

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Network connections of the hypothalamus

Figure 2 Time from incident ADS event to MS diagnosis

Presentation transcript:

Figure 2 Age-specific prevalence of common comorbidities in a prevalent multiple sclerosis cohort from Manitoba in 2010 (Refs 12,16) Figure 2 | Age-specific prevalence of common comorbidities in a prevalent multiple sclerosis cohort from Manitoba in 2010 (Refs 12,16). Individuals with multiple sclerosis were identified using population-based administrative (health claims) data. Comorbidities were identified using validated administrative case definitions. In 2010, the prevalence of these comorbidities was evaluated according to age group. The prevalence of physical comorbidities increased with age. The prevalence of psychiatric comorbidities did not differ substantially across age groups. Marrie, R. A. (2017) Comorbidity in multiple sclerosis: implications for patient care Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.33